THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.24] ID: TIP-MED-000456 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Risperidone & Olanzapine

Active Ingredient / Scientific Identity: Risperidone & Olanzapine • Class: Second-Generation (Atypical) Serotonin-Dopamine (5-HT2A/D2) Antagonist Antipsychotics (Schedule H | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NameRisperidone & Olanzapine ([11.24])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSecond-Generation (Atypical) Serotonin-Dopamine (5-HT2A/D2) Antagonist Antipsychotics (Sch
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationSchedule H1 (Rx — 3-Year Register Retention & Red-Border Warning)
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 (Rx — 3-Year Register Retention & Red-Bo🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Risperidone & Olanzapine (TIP-MED-000456, Reference Code [11.24]) is classified under CNS & Psychiatric Medicines as a Second-Generation (Atypical) Serotonin-Dopamine (5-HT2A/D2) Antagonist Antipsychotics (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H1 (Rx — 3-Year Register Retention & Red-Border Warning).

Verified Indian Market Examples / Compendial Status:
Representative Indian Formulations (for identification only): Risperidone: Sizodon (Sun), Risdone (Intas), Risperdal (J&J), Respidon (Torrent). Olanzapine: Oleanz (Sun), Oliza (Intas), Olimelt (MD), Zyprexa; | Strengths: Risperidone Tablets / MD: 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg; Oral Solution: 1 mg/mL; Long-Acting Depot Injection: 25/37.5/50 mg q2w. Olanzapine Tablets / Mouth-Dissolving (MD): 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg; IM Injection: 10 mg
Representative Indian Formulations (for identification only): Risperidone: Sizodon (Sun), Risdone (Intas), Risperdal (J&J), Respidon (Torrent). Olanzapine: Oleanz (Sun), Oliza (Intas), Olimelt (MD), Zyprexa; | Strengths: Risperidone Tablets / MD: 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg; Oral Solution: 1 mg/mL; Long-Acting Depot Injection: 25/37.5/50 mg q2w. Olanzapine Tablets / Mouth-Dissolving (MD): 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg; IM Injection: 10 mg
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Established pharmacological class action (Second-Generation (Atypical) Serotonin-Dopamine (5-HT2A/D2) Antagonist Antipsychotics (Schedule H | NLEM 2022)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Schizophrenia and other psychotic disorders, acute manic or mixed episodes in Bipolar I Disorder, treatment-resistant depression (Olanzapine + Fluoxetine), and severe refractory aggression/psychosis in autism or dementia (short-term <=6 weeks at 0.

4. Therapeutic Indications & Evidence-Supported Uses

  • Schizophrenia and other psychotic disorders, acute manic or mixed episodes in Bipolar I Disorder, treatment-resistant depression (Olanzapine + Fluoxetine), and severe refractory aggression/psychosis in autism or dementia (short-term <=6 weeks at 0
  • 25–0
  • 5 mg only when non-pharmacological measures fail!)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Risperidone (Schizophrenia/Mania): Start 1–2 mg/day PO (OD or BD), titrate to target **2–4 mg/day** (Doses >6 mg/day cause high EPS without added efficacy!; in Elderly/CKD/Hepatic: Start 0.25–0.5 mg BD!). (Duration: Long-term relapse prevention in schizophrenia/bipolar disorder; taper gradually when discontinuing)

Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified) | Food & Meal Timing: May be taken with or without food; Mouth-Dissolving (MD) tablets dissolve on tongue in seconds (useful in acute psychiatric agitation/non-adherence) | Best Time of Day: Bedtime (HS — leverages sedation for sleep and reduces daytime orthostasis) or BD (Risperidone)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Renal & Hepatic: Risperidone active metabolite (9-OH-risperidone / Paliperidone) is renally cleared -> halve Risperidone starting and maintenance doses (0.5 mg BD) if CrCl <30 mL/min or in cirrhosis! Olanzapine: Start at 2.5–5 mg OD in hepatic impairment
Elimination & Renal Adjustment:
Renal & Hepatic: Risperidone active metabolite (9-OH-risperidone / Paliperidone) is renally cleared -> halve Risperidone starting and maintenance doses (0.5 mg BD) if CrCl <30 mL/min or in cirrhosis! Olanzapine: Start at 2.5–5 mg OD in hepatic impairment
Hepatic Impairment Considerations:
Renal & Hepatic: Risperidone active metabolite (9-OH-risperidone / Paliperidone) is renally cleared -> halve Risperidone starting and maintenance doses (0.5 mg BD) if CrCl <30 mL/min or in cirrhosis! Olanzapine: Start at 2.5–5 mg OD in hepatic impairment

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • BOXED WARNING — INCREASED MORTALITY & CEREBROVASCULAR STROKE IN ELDERLY DEMENTIA PATIENTS: All atypical and typical antipsychotics increase all-cause mortality (1
  • 6–1
  • 7x, primarily from pneumonia, heart failure, & sudden cardiac death) and stroke/TIA in elderly patients with dementia-related psychosis! Contraindicated in coma/severe CNS d

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Risperidone (High D2 & Alpha-1 affinity): Dose-dependent **Hyperprolactinaemia** (highest among atypicals along with Amisulpride/Paliperidone -> galactorrhoea, amenorrhoea, gynaecomastia, sexual dysfunction, osteoporosis!), dose-dependent EPS/akathisia (at >4
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Risperidone: CYP2D6 inhibitors (Fluoxetine, Paroxetine, Bupropion, Terbinafine) increase active moiety levels
  • Carbamazepine/Phenytoin reduce Risperidone levels by 50%

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • FOUR VITAL COUNTER RULES: (1) Avoid standalone Sizodon Plus / Risdone Plus (fixed-dose Risperidone + Trihexyphenidyl) in older patients or long-term unless EPS is actually present
  • (2) On Oleanz/Oliza, weigh yourself weekly, watch for increased thirst/urination (high blood sugar), and exercise/limit sweets from Day 1

Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Risperidone Tablets / MD: 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg; Oral Solution: 1 mg/mL; Long-Acting Depot Injection: 25/37.5/50 mg q2w. Olanzapine Tablets / Mouth-Dissolving (MD): 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg; IM Injection: 10 mg). Missed-Dose Rule: Take at bedtime as soon as remembered; never double dose or stop suddenly

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.